The Role of Cancer Cooperative Groups within the Spectrum of Cancer Care

Kelahan A.M. , Catalano R. , Marinucci D. The history, structure, and achievements of the cancer cooperative groups. Managed Care Cancer. 2001: 28–33. Available at http://www.cancernetwork.com/. Accessed October 20, 2003.

Wittes R.E. , Friedman M.A. Accrual to clinical trials. J Natl Cancer Inst. 1988; 80: 884–885.

Gelber R.D. , Goldhirsch A. Can a clinical trial be the treatment of choice for patients with cancer? J Natl Cancer Inst. 1988; 80: 886–887.

Lara P.N. Jr , Higdon R. , Lim N. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001; 19: 1728–1733.

Levels of Evidence for Cancer Treatment Studies: Definition and Use (PDQ). Available at http://www.nci.nih.gov/cancerinfo/pdq/levels-evidence-adult-treatment. Accessed on October 29, 2003.

Cochrane A.L. Archie Cochrane in his own words: selections arranged from his 1972 introduction to “Effectiveness and Efficiency: Random Reflections on the Health Services”1972. Control Clin Trials. 1989; 10: 428–433.

Kaluzney A. , Brawley O. , Garson-Angert D. Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the minority-based Community Clinical Oncology Program. J Natl Cancer Inst. 1993; 85: 1945–1950.

Hunter C.P. , Frelick R.W. , Feldman A.R. Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log. Cancer Treat Rep. 1987; 71: 559–565.

Begg C.B. Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer. Bull Cancer. 1987; 74: 197–203.

McCaskill-Stevens W. , Pinto H. , Marcus A.C. Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. J Clin Oncol. 1999; 17: 1029–1039.

Byar D.P. Why data bases should not replace randomized clinical trials. Biometrics. 1980; 36: 337–342.

Micciolo R. , Valagussa P. , Marubini E. The use of historical controls in breast cancer: an assessment in three consecutive trials. Control Clin Trials. 1985; 6: 259–270.

Dupont W.D. Randomized vs historical clinical trials: are the benefits worth the costs? Am J Epidemiol. 1985; 122: 940–946.

Stiller C.A. Centralised treatment, entry to trials and survival. Br J Cancer. 1994; 70: 352–362.

Ries L.A.G. , Eisner M.P. , Kosary C.L. , eds. SEER Cancer Statistics Review, 1975-2000. Bethesda, Md: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2000. Accessed October 28, 2003.

Lukens J.N. Progress resulting from clinical trials: solid tumors in childhood cancer. Cancer. 1994; 74: 2710–2718.

Ross J.A. , Severson R.K. , Pollock B.H. Childhood cancer in the United States: a geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups. Cancer. 1996; 77: 201–207.

Anderson B.D. , Smith M.A. , Reaman G.H. Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst. 2003; 95: 630–631.

Fisher B. , Jeong J.H. , Anderson S. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002; 347: 567–575.

Fisher B. , Anderson S. , Bryant J. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347: 1233–1241.

Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer. 1999; 35: 1963–1973.

Goldhirsch A. , Glick J.H. , Gelber R.D. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001; 19: 3817–3827.

Moertel C.G. Accomplishments in surgical adjuvant therapy for large bowel cancer. Cancer. 1992; 70: 1364–1371.

Whitney C.W. , Sause W. , Bundy B.N. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17: 1339–1348.

Morris M. , Eifel P.J. , Lu J. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340: 1137–1143.

Keys H.M. , Bundy B.N. , Stehman F.B. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999; 340: 1154–1161.

Rose P.G. , Bundy B.N. , Watkins E.B. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340: 1144–1153.

Peters WA III , Liu P.Y. , Barrett RJ II . Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18: 1606–1613.

NCI Clinical Alert Urges New Standard of Care for Invasive Cervical Cancer. Available at http://www.nci.nih.gov/clinicaltrials/developments/cervical-cancer-alert0600. Accessed on October 28, 2003.

McGuire W.P. , Hoskins W.J. , Brady M.F. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334: 1–6.

Piccart M.J. , Bertelsen K. , James K. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000; 92: 699–708.

Kirkwood J.M. , Strawderman M.H. , Ernstoff M.S. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 7–17.

Kirkwood J.M. , Ibrahim J.G. , Sondak V.K. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000; 18: 2444–2458.

Kirkwood J.M. , Ibrahim J.G. , Sosman J.A. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001; 19: 2370–2380.

Fisher B. , Costantino J.P. , Wickerham D.L. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 1371–1388.

Thompson I.M. , Goodman P.J. , Tangen C.M. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215–224.

Sandler R.S. , Halabi S. , Baron J.A. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003; 348: 883–90. N Engl J Med. 2003; 348: 1939.

Rothenberg M.L. , Meropol N.J. , Poplin E.A. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001; 19: 3801–3807.

Sargent D.J. , Goldberg R.M. , Mahoney M.R. Rapid reporting and review of an increased incidence of a known adverse event. J Natl Cancer Inst. 2000; 92: 1011–1013.

Peters W.P. , Rosner G. , Vredenburgh J. Updated results of a prospective, randomized comparison of two doses of combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13. Proc Annu Meet Am Soc Clin Oncol. 2001; 20: 81. Abstract.

Tallman M.S. , Gray R. , Robert N.J. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003; 349: 17–26.

National Library of Medicine. Medical subject headings. Available at http://www.nlm.nih.gov/mesh/. Accessed October 28, 2003.

Lee S.J. , Earle C.C. , Weeks J.C. Outcomes research in oncology: history, conceptual framework, and trends in the literature. J Natl Cancer Inst. 2000; 92: 195–204.

Gotay C.C. , Moinpour C.M. , Moody-Thomas S. Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience. J Natl Cancer Inst. 2000; 92: 1381–1387.

Bennett C.L. , Golub R. , Waters T.M. Economic analysis of phase III cooperative group trials: are they feasible? Cancer Invest. 1997; 15: 227–236.

Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook. J Natl Cancer Inst Monogr. 1998; 24: 1–28.

Schulman K.A. , Yabroff K.R. Measuring the cost-effectiveness of cancer care. Oncology (Huntingt). 1995; 9: 523–538.

Rubio-Terres C. , Tisaire J.L. , Kobina S. Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. Lung Cancer. 2002; 35: 81–89.

Konski A. , Bracy P. , Weiss S. Cost-utility analysis of a malignant glioma protocol. Int J Radiat Oncol Biol Phys. 1997; 39: 575–578.

Owen J.B. , Grigsby P.W. , Caldwell T.M. Can costs be measured and predicted by modeling within a cooperative clinical trial group? Economic methodologic pilot studies of the Radiation Therapy Oncology Group (RTOG) studies 90-03 and 91-04. Int J Radiat Oncol Biol Phys. 2001; 49: 633–639.

Comis R.L. The cooperative groups: past and future. Cancer Chemother Pharmacol. 1998; 42: 585–587.

Cella D.F. , Orav E.J. , Kornblith A.B. Socioeconomic status and cancer survival. J Clin Oncol. 1991; 9: 1500–1509.

Modiano M.R. , Villar-Werstler P. , Crowley J. Evaluation of race as a prognostic factor in multiple myeloma: an ancillary of Southwest Oncology Group Study 8229. J Clin Oncol. 1996; 14: 974–977.

Roach M III , Cirrincione C. , Budman D. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am. 1997; 3: 107–112.

Dignam J.J. , Colangelo L. , Tian W. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 1999; 91: 1933–1940.

Yancik R. , Ries L.A. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000; 14: 17–23.

Balducci L. , Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000; 5: 224–237.

Begg C.B. , Carbone P.P. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer. 1983; 52: 1986–1992.

Dixon D.O. , Neilan B. , Jones S.E. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986; 4: 295–305.

Sargent D.J. , Goldberg R.M. , Jacobson S.D. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 1091–1097.

Langer C.J. , Manola J. , Bernardo P. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002; 94: 173–181.

Rocha Lima C.M. , Herndon JE II , Kosty M. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002; 94: 181–187.

Pajak T.F. , Clark G.M. , Sargent D.J. Statistical issues in tumor marker studies. Arch Pathol Lab Med. 2000; 124: 1011–1015.

Schilsky R.L. , Dressler L.M. , Bucci D. Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res. 2002; 8: 943–948.

Parmar M.K. , Ungerleider R.S. , Simon R. Assessing whether to perform a confirmatory randomized clinical trial. J Natl Cancer Inst. 1996; 88: 1645–1651.

Berry D.A. When is a confirmatory randomized clinical trial needed? J Natl Cancer Inst. 1996; 88: 1606–1607.

Rockette H.E. , Redmond C.K. Limitations and advantages of meta-analysis in clinical trials. Recent Results Cancer Res. 1988; 111: 99–104.

Pignon J.P. , Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol. 2001; 2: 475–482.

Eifel P. , Axelson J.A. , Costa J. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst. 2001; 93: 979–989.

Kosecoff J. , Kanouse D.E. , Rogers W.H. Effects of the National Institutes of Health Consensus Development Program on physician practice. JAMA. 1987; 258: 2708–2713.

Rusch V.W. Surgeons: a future role in clinical trials? Oncologist. 1997; 2: V–VI.

Stocchi L. , Nelson H. , Sargent D.J. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol. 2001; 19: 3895–3902.

Haase G.M. The implications of surgical quality assurance in cancer clinical trials. Cancer. 1994; 74: 2630–2637.

Mandelblatt J.S. , Yabroff K.R. , Kerner J.F. Equitable access to cancer services: a review of barriers to quality care. Cancer. 1999; 86: 2378–2390.

Paik S. Incorporating genomics into the cancer clinical trial process. Semin Oncol. 2001; 28: 305–309.

Dignam J.J. , Bryant J. , Paik S. Statistical considerations in assessing molecular markers of cancer prognosis and treatment efficacy. In: Looney S.W. , ed. Biostatistical Methods. Totowa, NJ: Humana Press; 2002.

Tejeda H.A. , Green S.B. , Trimble E.L. Representation of African-Americans, Hispanics, and Whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996; 88: 812–816.

Bleyer W.A. , Tejeda H.A. , Murphy S.B. Equal participation of minority patients in US national pediatric cancer clinical trials. J Pediatr Hematol Oncol. 1997; 19: 423–427.

Moinpour C.M. , Atkinson J.O. , Thomas S.M. Minority recruitment in the prostate cancer prevention trial. Ann Epidemiol. 2000; 10: S85–S91.

Ellis P.M. , Butow P.N. , Tattersall M.H. Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol. 2001; 19: 3554–3561.